SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. today announced that David A. Bushinsky, M.D., will deliver a podium presentation at the American Society of Nephrology (ASN) Annual Kidney Week meeting, taking place November 1-5, 2017 in New Orleans, on the results of Tricida’s successful Phase 1/2 study of TRC101. TRC101 is Tricida’s lead drug candidate, a first-in-class approach to the treatment of metabolic acidosis currently being investigated in an ongoing Phase 3 study. Dr. Bushinsky is the John J. Kuiper Distinguished Professor of Medicine and of Pharmacology and Physiology at the University of Rochester School of Medicine.
Podium Presentation Title: TRC101, a Novel Hydrochloric Acid
Binder, Increases Serum Bicarbonate in Acidemic Patients with Chronic
Kidney Disease
Presenter: David A. Bushinsky, M.D., John J.
Kuiper Distinguished Professor of Medicine and of Pharmacology and
Physiology at the University of Rochester School of Medicine
Session
Date & Time: November 4, 2017 from 4:30 PM to 6:30 PM EDT
Presentation
Time: November 4, 2017 at 6:18 PM EDT
Session Room: Room
385 (Morial Convention Center)
Abstract Program #: SA-OR070
About TRC101
TRC101 is being developed as a first-in-class, orally administered, counterion-free, insoluble, non-absorbed drug for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD).
About CKD and Metabolic Acidosis
In the United States, approximately 1 in 7 adults has CKD, a progressive and often-times debilitating disease. Patients with CKD may have a reduced ability to excrete acid generated by intrinsic and dietary metabolism, especially protein, resulting in metabolic acidosis. Metabolic acidosis results in lower blood pH and decreased blood bicarbonate levels. Chronic metabolic acidosis can lead to accelerated progression of kidney disease, an increased rate of mortality, progressive muscle breakdown and exacerbation of bone disease. In the United States, chronic metabolic acidosis affects a significant percentage of CKD patients resulting in approximately 3 million to 4 million adults with chronic metabolic acidosis. There are no FDA-approved treatments for chronic metabolic acidosis.
About Tricida
Tricida, Inc. is a privately-held, clinical stage, biopharmaceutical company focused on the discovery and development of non-absorbed therapies. Tricida’s lead investigational drug candidate, TRC101, represents a first-in-class approach to the treatment of metabolic acidosis, a common complication of CKD that can result in accelerated progression of kidney disease, an increased rate of mortality, progressive muscle breakdown and exacerbation of bone disease. In January 2016, the FDA accepted Tricida’s Investigational New Drug (IND) application for TRC101. The company has since successfully completed a Phase 1/2 double-blind, placebo-controlled study in which the safety, tolerability and efficacy of TRC101 were evaluated in subjects with chronic kidney disease and low serum bicarbonate and is currently conducting a Phase 3 study of TRC101 for the treatment of metabolic acidosis associated with CKD.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, including, for example, potential therapeutic capabilities, potential medical need and market size, and our expected timeline of development. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. For example, many drug candidates entering Phase 3 trials do not become approved drugs. The forward-looking statements contained in this press release reflect Tricida’s current views with respect to future events, and Tricida does not undertake and specifically disclaims any obligation to update any forward-looking statements.
For more information, visit www.tricida.com.
